European Commission proposes SPC waiver to boost generics

The European Commission has proposed a change in IP rules to allow pharmaceutical companies to produce generic drugs for export to non-EU countries that don’t have patent protection.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

LSPN Europe 2018: SPCs—important but ‘phenomenally complicated’, say lawyers

16 November 2018 Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.

Big Pharma

EFPIA warns that SPC waiver will weaken EU IP framework

18 October 2018 The supplementary protection certificate manufacturing waiver “sends a worrying global signal that the EU is weakening its IP framework”, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Big Pharma

SPC waiver proposal could discourage innovation, says pharma group

9 August 2018 A proposed change to supplementary protection certificate rules in the EU could lead to the development of less innovative medicines, according to the Irish Pharmaceutical Healthcare Association.